arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Alnylam Pharmaceuticals, Inc.

ALNY Health Care Biotechnology: Pharmaceutical Preparations
$266.11
Today
as of Sep 4, 16:45 ET
Last 30 days -7.73% Jul 28 → Sep 04
$198.85 $222.90 $246.94 $270.99 $295.04 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$258.58
High
$266.85
Low
$258.02
Volume
$1M
Avg Vol
$1M
Mkt Cap
$28.9B
P/E (TTM)
87.25
Beta
—
52w High
$495.55
52w Low
$197.81
Div Yield
—
Shares Out
$134M

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 0 ● 22 ▼ 3
Sep 4 · 15:15 MT Newswires neutral
Alnylam's Zilebesiran Sees Commercial Opportunity From Baxfendy Launch, Oppenheimer Says
Sep 2 · 12:00 PR Business Wire neutral
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 31 · 15:40 MT Newswires neutral
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$198
$496
23% of range
Avg surprise (last 2)
+33.2%
Avg reaction (last 1)
-3.1%
0% positive
Latest IV / EM
46%
EM ±7.2% · $270 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.21$-1.20$-0.19$0.83$1.84 Actual $-1.40Actual $-2.21Actual $1.15Actual $-0.52Actual $-0.13Actual $-0.87Actual $-0.44Est $1.00Actual $-0.52Est $-0.58Actual $1.84Actual $1.21 MarJunSepMarJunSepMar/2025Jun/2025SepJun
Revenue vs Net Income Revenue Net income
$-112M$255M$622M$989M$1.4B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $1.21 — — — — financials
Tue Sep 30, 2025Sep 2025 $1.84 — — — — financials
Thu Jul 31, 2025Jun/2025 $-0.52 $-0.58 +10.3% — — earnings
Thu May 1, 2025Mar/2025 $-0.44 $1.00 +56.0% — -3.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.87 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.13 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.52 — — — — financials
Sat Sep 30, 2023Sep 2023 $1.15 — — — — financials
Fri Jun 30, 2023Jun 2023 $-2.21 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.40 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1.29B——$1.25B$774M$594M—$501M
Cost of revenue$298M——$197M$142M$70M—$82M
Gross profit————————
Operating income$231M——$368M$-16M$18M—$-77M
Net income$164M$206M—$251M$-72M$-18M—$-112M
EPS (diluted)$1.21——$1.84$-0.55——$-0.87

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$1.71B—$1.66B$1.49B$1.11B$1.02B$966M$1.10B
Inventory$97M—$83M$75M$72M$66M$79M$76M
Total current assets$4.62B—$4.05B$3.95B$3.64B$3.27B$3.30B$3.36B
Total assets$5.56B—$4.97B$4.85B$4.57B$4.21B$4.24B$4.21B
Long-term debt————————
Total liabilities$4.20B—$4.18B$4.62B$4.32B$4.10B$4.17B$4.17B
Total equity$1.35B$1.08B$789M$234M$555M$426M$67M$32M

Implied volatility — last 90 days

33%41%49%58%66% Jun 07 — IV 49% · EM ±6.7%Jun 08 — IV 44% · EM ±5.8%Jun 09 — IV 46% · EM ±5.7%Jun 10 — IV 43% · EM ±5.1%Jun 11 — IV 43% · EM ±4.8%Jun 12 — IV 44% · EM ±4.5%Jun 15 — IV 51% · EM ±3.7%Jun 16 — IV 53% · EM ±3.2%Jun 17 — IV 62% · EM ±2.6%Jun 19 — IV 47% · EM ±10.4%Jun 22 — IV 47% · EM ±9.8%Jun 23 — IV 46% · EM ±9.5%Jun 24 — IV 48% · EM ±9.7%Jun 25 — IV 47% · EM ±9.2%Jun 26 — IV 46% · EM ±8.9%Jun 29 — IV 45% · EM ±8.1%Jun 30 — IV 45% · EM ±7.8%Jul 01 — IV 46% · EM ±7.7%Jul 02 — IV 44% · EM ±7.1%Jul 03 — IV 46% · EM ±7.1%Jul 06 — IV 49% · EM ±6.8%Jul 07 — IV 48% · EM ±6.3%Jul 08 — IV 50% · EM ±6.2%Jul 09 — IV 49% · EM ±5.7%Jul 10 — IV 43% · EM ±4.7%Jul 13 — IV 53% · EM ±4.4%Jul 14 — IV 56% · EM ±4.1%Jul 15 — IV 57% · EM ±3.4%Jul 16 — IV 66% · EM ±2.8%Jul 20 — IV 56% · EM ±13.2%Jul 21 — IV 56% · EM ±13.0%Jul 22 — IV 59% · EM ±13.5%Jul 23 — IV 57% · EM ±12.8%Jul 24 — IV 57% · EM ±12.5%Jul 27 — IV 61% · EM ±12.7%Jul 28 — IV 58% · EM ±11.8%Jul 29 — IV 58% · EM ±11.6%Jul 30 — IV 58% · EM ±11.3%Jul 31 — IV 51% · EM ±9.8%Aug 03 — IV 47% · EM ±8.3%Aug 04 — IV 50% · EM ±8.6%Aug 05 — IV 43% · EM ±7.2%Aug 06 — IV 47% · EM ±7.6%Aug 07 — IV 44% · EM ±6.9%Aug 10 — IV 48% · EM ±6.7%Aug 11 — IV 41% · EM ±5.5%Aug 12 — IV 43% · EM ±5.4%Aug 13 — IV 42% · EM ±5.0%Aug 14 — IV 33% · EM ±3.7%Aug 17 — IV 49% · EM ±4.1%Aug 18 — IV 45% · EM ±3.3%Aug 19 — IV 54% · EM ±3.2%Aug 20 — IV 57% · EM ±2.4%Aug 24 — IV 44% · EM ±9.2%Aug 25 — IV 43% · EM ±8.7%Aug 26 — IV 49% · EM ±9.8%Aug 27 — IV 52% · EM ±10.1%Aug 28 — IV 45% · EM ±8.6%Aug 31 — IV 44% · EM ±7.7%Sep 01 — IV 44% · EM ±7.5%Sep 02 — IV 44% · EM ±7.4%Sep 03 — IV 43% · EM ±6.9%Sep 04 — IV 46% · EM ±7.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in